🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Georg A. Bjarnason

Sunnybrook Health Science Centre

ORCID: 0000-0001-6903-5357

Also affiliated with University of Toronto, Health Sciences Centre

MedicineBiochemistry, Genetics and Molecular BiologyEconomics, Econometrics and Finance

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

2in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 5 papers. Top paper: “A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial”.

A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial

The Lancet(2021)10.1016/s0140-6736(21)00152-5

N/A

6.9DataRank · unranked

283 citations

Catherine M. Tangen, Ian M. Thompson, Naomi Balzer-Haas, Daniel J. George, Daniel Y.C. Heng +15 more

Real-world Assessment of Clinical Outcomes in Patients with Metastatic Renal Cell Carcinoma with or Without Sarcomatoid Features Treated with First-line Systemic Therapies

European Urology Oncology(2024)10.1016/j.euo.2023.11.016

N/A

0.543DataRank · unranked

11 citations

Alice Dragomir, Lori A. Wood, Christian Kollmannsberger, Naveen S. Basappa, Anil Kapoor +15 more

Cabozantinib after prior checkpoint inhibitor therapy in patients with solid tumors: A systematic literature review

Cancer Treatment Reviews(2022)10.1016/j.ctrv.2022.102453

N/A

0.292DataRank · unranked

6 citations

Arndt Vogel, Ann-Lii Cheng, Georg A. Bjarnason, Joel W. Neal, Jeffrey Graham

Sunitinib versus cabozantinib, crizotinib or savolitinib in metastatic papillary renal cell carcinoma (pRCC): Results from the randomized phase II SWOG 1500 study.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.6_suppl.270

N/A

0DataRank · unranked

9 citations

Catherine M. Tangen, Ian M. Thompson, Naomi B. Haas, Daniel J. George, Daniel Yick Chin Heng +15 more

Erratum to: Extended Disease Control with Unconventional Cabozantinib Dose Increase in Metastatic Renal Cell Carcinoma

Kidney Cancer(2023)10.3233/kca-229030

N/A

0DataRank · unranked

0 citations

Roy Elias, Alana Christie, Noelle S. Williams, Iván Pedrosa, Georg A. Bjarnason +2 more